CTOs on the Move


 
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cyteir.com
  • 128 Spring Street Building A, Suite 510
    Lexington, MA USA 02421
  • Phone: 857.285.4140

Executives

Name Title Contact Details

Funding

Cyteir raised $29M on 03/08/2018
Cyteir raised $40.2M on 10/15/2019
Cyteir raised $80M on 02/11/2021

Similar Companies

Quantum Immunologics

Quantum Immunologics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vesicare

Vesicare is a Northbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Interspond

Interspond is a Trial Management Organization (TMO) that works with a network of multi therapeutic sites across the country to facilitate clinical and pharmaceutical research and trials.

PharmaDerm

PharmaDerm is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanTheryx

PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.